Vertex Pharmaceuticals Inc (VRTX.OQ)
19 Jan 2018
* VERTEX AND CRISPR THERAPEUTICS TO CO-DEVELOP AND CO-COMMERCIALIZE CTX001 AS CRISPR/CAS9 GENE EDITED TREATMENT FOR SICKLE CELL DISEASE AND Β-THALASSEMIA
* VERTEX ANNOUNCES POSITIVE RESULTS FROM OPEN-LABEL PHASE 3 STUDY OF KALYDECO® (IVACAFTOR) IN CHILDREN WITH CYSTIC FIBROSIS AGES 1 TO 2 YEARS
BRIEF-Vertex receives CHMP positive opinion for Orkambi for the treatment of children with cystic fibrosis ages 6-11
* Vertex receives CHMP positive opinion for Orkambi® (lumacaftor/ivacaftor) for the treatment of children with cystic fibrosis ages 6-11 with two copies of the f508del mutation in the European Union Source text for Eikon: Further company coverage:
Oct 25 Vertex Pharmaceuticals Inc reported a wider third-quarter net loss on Wednesday, on higher costs and onetime items, and raised its outlook for full-year sales of its key cystic fibrosis drugs.
BRIEF-Vertex says FDA sets action date of Feb 28, 2018 for its Tezacaftor/Ivacaftor Combination Treatment
* Vertex announces acceptance of its applications for review of the tezacaftor/ivacaftor combination treatment in people with cystic fibrosis by the FDA and EMA
BRIEF-FDA approves Kalydeco(Ivacaftor) for more than 600 people ages 2 and older with Cystic Fibrosis who have certain residual function mutations
* FDA approves Kalydeco (Ivacaftor) for more than 600 people ages 2 and older with Cystic Fibrosis who have certain residual function mutations
* Vertex says interested in acquiring early stage assets in disease areas consistent with cystic fibrosis
July 26 Vertex Pharmaceuticals Inc reported a better-than-expected profit for the third straight quarter, helped by improved sales of its cystic fibrosis (CF) drugs.
July 26 Vertex Pharmaceuticals Inc reported a quarterly profit, compared with a year-ago loss, helped by higher sales of its cystic fibrosis (CF) drugs.
- Vertex Pharmaceuticals: Set To Wow In '18
- 3 Things In Biotech You Should Learn Today: January 13, 2018
- Your Daily Pharma Scoop: Roche Highlights Pipeline, GenSight Gets Nod To Start Trial, Bluebird Presents At JPM
- When The Bulls Growl And The Bears Moo - Stock Market Outlook 2018
- Your Daily Pharma Scoop: Ablynx Takeover Bid, Celgene Acquires Impact Biomedicines, Axovant Flops Again
- Valuation Dashboard In Healthcare - New Year's Update